ECSP13012473A - Forma de dosificación resistente a alteración que comprende un polímero aniónico - Google Patents
Forma de dosificación resistente a alteración que comprende un polímero aniónicoInfo
- Publication number
- ECSP13012473A ECSP13012473A ECSP13012473A ECSP13012473A EC SP13012473 A ECSP13012473 A EC SP13012473A EC SP13012473 A ECSP13012473 A EC SP13012473A EC SP13012473 A ECSP13012473 A EC SP13012473A
- Authority
- EC
- Ecuador
- Prior art keywords
- dosage form
- anionic polymer
- form including
- resistant dosage
- polysaccharide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a una forma de dosificación farmacéutica que muestra una resistencia a rompimiento de al menos 500 N, dicha forma de dosificación conteniendo un ingrediente farmacológicamente activo (A); un polisacárido aniónico (B) que se obtiene al introducir grupos funcionales aniónicos, en forma protonada o una sal fisiológicamente aceptable del mismo, en un polisacárido; y un óxido de polialquileno (C); en donde el ingrediente farmacológicamente activo (A) está presente en una matriz de liberación controlada comprendiendo el polisacárido aniónico (B) y el óxido de polialquileno (C).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10009124 | 2010-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP13012473A true ECSP13012473A (es) | 2013-04-30 |
Family
ID=43897069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP13012473 ECSP13012473A (es) | 2010-09-02 | 2013-03-01 | Forma de dosificación resistente a alteración que comprende un polímero aniónico |
Country Status (22)
Country | Link |
---|---|
US (1) | US20120059065A1 (es) |
EP (1) | EP2611428B1 (es) |
JP (1) | JP5925778B2 (es) |
KR (1) | KR20130097201A (es) |
CN (2) | CN107308124A (es) |
AR (1) | AR082861A1 (es) |
AU (1) | AU2011297954B2 (es) |
BR (1) | BR112013005195A2 (es) |
CA (1) | CA2808988C (es) |
CL (1) | CL2013000423A1 (es) |
CO (1) | CO6670598A2 (es) |
EC (1) | ECSP13012473A (es) |
ES (1) | ES2534847T3 (es) |
HK (1) | HK1184389A1 (es) |
IL (1) | IL224616A (es) |
MX (1) | MX340427B (es) |
NZ (1) | NZ607479A (es) |
PE (1) | PE20131125A1 (es) |
PL (1) | PL2611428T3 (es) |
RU (1) | RU2013114411A (es) |
TW (1) | TWI501788B (es) |
WO (1) | WO2012028317A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
WO2004084868A1 (en) | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102004032051A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
WO2008148798A2 (en) | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
RU2493830C2 (ru) | 2008-01-25 | 2013-09-27 | Грюненталь Гмбх | Лекарственная форма |
BRPI0912014A2 (pt) | 2008-05-09 | 2019-03-06 | Grünenthal GmbH | processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização |
AU2010211220B2 (en) | 2009-02-06 | 2013-08-01 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
KR101747156B1 (ko) * | 2009-07-22 | 2017-06-27 | 그뤼넨탈 게엠베하 | 산화-안정화된 탬퍼-내성 용량형 |
TW201105316A (en) | 2009-07-22 | 2011-02-16 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
ES2606227T3 (es) * | 2010-02-03 | 2017-03-23 | Grünenthal GmbH | Preparación de una composición farmacéutica en polvo mediante una extrusora |
CN103179954A (zh) | 2010-09-02 | 2013-06-26 | 格吕伦塔尔有限公司 | 包含阴离子聚合物的抗破碎剂型 |
PE20131102A1 (es) | 2010-09-02 | 2013-10-12 | Gruenenthal Chemie | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica |
PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
MX348491B (es) | 2011-07-29 | 2017-06-15 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco. |
WO2013127831A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
AU2013248351B2 (en) | 2012-04-18 | 2018-04-26 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
WO2014006004A1 (en) | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
BR112015000320B1 (pt) | 2012-07-12 | 2023-03-07 | SpecGx LLC | Composições farmacêuticas dissuasivas de abuso e seu processo de preparação |
AR096439A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido que contiene una o más partículas |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
EP3142646A1 (en) | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
ES2809458T3 (es) | 2014-07-17 | 2021-03-04 | Pharmaceutical Manufacturing Res Services Inc | Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
AU2016251854A1 (en) | 2015-04-24 | 2017-10-19 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
CA2983648A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
WO2016170096A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
MX2017013633A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. |
US10183018B2 (en) | 2015-05-28 | 2019-01-22 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
US11234974B2 (en) | 2015-05-28 | 2022-02-01 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
CA3032598A1 (en) | 2016-08-01 | 2018-02-08 | Grunenthal Gmbh | Tamper resistant dosage form comprising an anionic polysaccharide |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3612211A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
US5900425A (en) * | 1995-05-02 | 1999-05-04 | Bayer Aktiengesellschaft | Pharmaceutical preparations having controlled release of active compound and processes for their preparation |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US6471120B1 (en) * | 2001-10-25 | 2002-10-29 | Colgate Palmolive Company | Easy opening handled carton |
DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
WO2004084868A1 (en) * | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US8075872B2 (en) * | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
EP1658054B1 (de) * | 2003-08-06 | 2007-06-27 | Grünenthal GmbH | Gegen missbrauch gesicherte darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
EP1740156B8 (de) | 2004-04-22 | 2012-07-11 | Grünenthal GmbH | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform |
AR049562A1 (es) * | 2004-07-01 | 2006-08-16 | Gruenenthal Gmbh | Formas farmaceuticas orales, con liberacion controlada de opioides, protegidas frente al abuso y procedimiento para su preparacion |
EP1765298B1 (de) | 2004-07-01 | 2012-10-24 | Gruenenthal Gmbh | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders |
KR101204657B1 (ko) | 2004-07-01 | 2012-11-27 | 그뤼넨탈 게엠베하 | (1r,2r)-3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀을 함유하는 남용 방지 경구 투여 제형 |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
RU2433817C2 (ru) * | 2006-01-21 | 2011-11-20 | Эбботт Гмбх Унд Ко.Кг | Лекарственная форма и способ для доставки вызывающих зависимость лекарственных веществ |
DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
RU2493830C2 (ru) | 2008-01-25 | 2013-09-27 | Грюненталь Гмбх | Лекарственная форма |
KR100970665B1 (ko) * | 2008-02-04 | 2010-07-15 | 삼일제약주식회사 | 알푸조신 또는 그의 염을 함유하는 서방성 정제 |
EP2389169A1 (en) * | 2009-01-26 | 2011-11-30 | Egalet A/S | Controlled release formulations with continuous efficacy |
-
2011
- 2011-09-01 RU RU2013114411/15A patent/RU2013114411A/ru not_active Application Discontinuation
- 2011-09-01 NZ NZ607479A patent/NZ607479A/en not_active IP Right Cessation
- 2011-09-01 AR ARP110103191A patent/AR082861A1/es unknown
- 2011-09-01 BR BR112013005195A patent/BR112013005195A2/pt not_active IP Right Cessation
- 2011-09-01 MX MX2013002120A patent/MX340427B/es active IP Right Grant
- 2011-09-01 CN CN201710507176.XA patent/CN107308124A/zh active Pending
- 2011-09-01 ES ES11761000.6T patent/ES2534847T3/es active Active
- 2011-09-01 US US13/223,358 patent/US20120059065A1/en not_active Abandoned
- 2011-09-01 EP EP11761000.6A patent/EP2611428B1/en not_active Not-in-force
- 2011-09-01 JP JP2013526359A patent/JP5925778B2/ja not_active Expired - Fee Related
- 2011-09-01 WO PCT/EP2011/004404 patent/WO2012028317A1/en active Application Filing
- 2011-09-01 CA CA2808988A patent/CA2808988C/en not_active Expired - Fee Related
- 2011-09-01 PE PE2013000330A patent/PE20131125A1/es active IP Right Grant
- 2011-09-01 AU AU2011297954A patent/AU2011297954B2/en not_active Ceased
- 2011-09-01 TW TW100131418A patent/TWI501788B/zh not_active IP Right Cessation
- 2011-09-01 CN CN2011800420125A patent/CN103179956A/zh active Pending
- 2011-09-01 KR KR1020137008511A patent/KR20130097201A/ko not_active Application Discontinuation
- 2011-09-01 PL PL11761000T patent/PL2611428T3/pl unknown
-
2013
- 2013-02-07 IL IL224616A patent/IL224616A/en active IP Right Grant
- 2013-02-11 CO CO13027448A patent/CO6670598A2/es unknown
- 2013-02-12 CL CL2013000423A patent/CL2013000423A1/es unknown
- 2013-03-01 EC ECSP13012473 patent/ECSP13012473A/es unknown
- 2013-10-24 HK HK13111942.1A patent/HK1184389A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2611428A1 (en) | 2013-07-10 |
CA2808988C (en) | 2018-05-01 |
BR112013005195A2 (pt) | 2016-07-12 |
CO6670598A2 (es) | 2013-05-15 |
CN103179956A (zh) | 2013-06-26 |
CN107308124A (zh) | 2017-11-03 |
CA2808988A1 (en) | 2012-03-08 |
TWI501788B (zh) | 2015-10-01 |
KR20130097201A (ko) | 2013-09-02 |
MX340427B (es) | 2016-07-08 |
AU2011297954B2 (en) | 2014-05-15 |
EP2611428B1 (en) | 2015-01-14 |
CL2013000423A1 (es) | 2013-04-12 |
IL224616A (en) | 2017-06-29 |
TW201212954A (en) | 2012-04-01 |
ES2534847T3 (es) | 2015-04-29 |
US20120059065A1 (en) | 2012-03-08 |
HK1184389A1 (en) | 2014-01-24 |
AR082861A1 (es) | 2013-01-16 |
JP5925778B2 (ja) | 2016-05-25 |
PE20131125A1 (es) | 2013-10-21 |
PL2611428T3 (pl) | 2015-06-30 |
JP2013536809A (ja) | 2013-09-26 |
RU2013114411A (ru) | 2014-10-10 |
MX2013002120A (es) | 2013-04-03 |
AU2011297954A1 (en) | 2013-03-14 |
NZ607479A (en) | 2015-06-26 |
WO2012028317A1 (en) | 2012-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012473A (es) | Forma de dosificación resistente a alteración que comprende un polímero aniónico | |
ES2487244T3 (es) | Forma de dosificación resistente a la manipulación que comprende un polímero aniónico | |
ECSP13012474A (es) | Forma de dosificación resistente a manipulación que comprende una sal inorgánica | |
CY1120783T1 (el) | Ανθεκτικη εναντι παραβιασης και ανθεκτικη εναντι μεταποθηκευσης δοσης φαρμακευτικη μορφη δοσολογιας | |
AR096439A1 (es) | Forma de dosificación resistente al uso indebido que contiene una o más partículas | |
CO2017010744A2 (es) | Forma de dosificación resistente a alteraciones con liberación inmediata y resistencia contra la extracción por solventes | |
DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
MX2015016112A (es) | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. | |
UA106634C2 (uk) | Тверда фармацевтична дозована форма | |
ECSP10010416A (es) | Forma de dosificación farmaceutica | |
CL2014000904A1 (es) | Forma de dosis farmaceutica oral resistente a la ruptura que comprende i) un ingrediente farmacologicamente activo, ii) un antagonista opioide y/o un agente repelente, iii) un oxido de polialquileno y iv) un polimero anionico. | |
EA201400172A1 (ru) | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства | |
AR087871A1 (es) | Una composicion farmaceutica de rapida disolucion | |
PE20140255A1 (es) | Tableta dispersable en forma oral | |
HN2011003403A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas | |
ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
UY32650A (es) | Medicamento para la administración oral que contiene al menos un esterógeno y/o al menos un gestágeno y al menos una cepa de bacterias probióticas | |
CO6640318A2 (es) | Formas de dosificación oral de bendamustina | |
MX2010000120A (es) | Estereoisomeros de triciclodecan-9-il-xantogenato. | |
PE20130308A1 (es) | Metodos para tratar infecciones bacterianas recurrentes | |
PE20151282A1 (es) | Combinacion de medicamentos que comprenden fenilefrina y paracetamol | |
CO6460763A2 (es) | Métodos y formulaciones ectoparasiticidas | |
EA201070175A1 (ru) | Фармацевтическая композиция контролируемого высвобождения, содержащая толперизона гидрохлорид | |
EA200900173A1 (ru) | Фармацевтическая композиция для перорального применения | |
UA105513C2 (uk) | Лікарська форма уповільненого вивільнення глюкозаміну |